ITabMed announces the IND approval from NMPA for A-337, a CD3-activating bispecific antibody targeting EpCAM to treat solid tumors

ITabMed Ltd., a clinical-stage biotech company in China, announced the IND approval from China National Medical Products Administration for A-337, a CD3-activating bi-specific antibody targeting EpCAM.